Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The greedy nature of mutant RAS: a boon for drug discovery targeting cancer metabolism?

Acta biochimica et biophysica Sinica - 1 Jan 2016

Lv Jing, Wang Jieqiong, Chang Siyu, Liu Mingyao, Pang Xiufeng

Abstract excerpt

RAS oncogene mutations are frequently detected in human cancers. Among RAS-mediated tumorigenesis, KRAS-driven cancers are the most frequently diagnosed and resistant to current therapies. Despite more than three decades of intensive efforts, there are still no specific therapies for mutant RAS proteins. While trying to block those well-established downstream pathways, such as the RAF-MAPK pathway and the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Discovery
Share to Glutamine
Share to Glycolysis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Molecular Targeted Therapy

Share to Neoplasm Transplantation

Share to Phosphatidylinositol 3-Kinases

Share to Proto-Oncogene Proteins c-akt

Share to ras Proteins

Source

Identifiers

PMID: 26487443
DOI: 10.1093/abbs/gmv102

Genes

KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The greedy nature of mutant RAS: a boon for drug discovery targeting cancer metabolism?PMID 26487443Read ↗

Metabolic Dependencies in <i>RAS</i>-Driven CancersSemantic proximity Read ↗

Targeting KRAS: from metabolic regulation to cancer treatmentSemantic proximity Read ↗

Targeting metabolic reprogramming in KRAS-driven cancers.Semantic proximity Read ↗

Metabolic reprogramming in KRAS-mutant cancers: Proven targetable vulnerabilities and potential therapeutic strategies.Semantic proximity Read ↗

Cancer Metabolism: Phenotype, Signaling and Therapeutic Targets.Semantic proximity Read ↗

Lipid Metabolic Alterations in KRAS Mutant Tumors: Unmasking New Vulnerabilities for Cancer Therapy.Semantic proximity Read ↗

Targeting the RAS-dependent chemoresistance: The Warburg connection.Semantic proximity Read ↗

The metabolic landscape of RAS-driven cancers from biology to therapySemantic proximity Read ↗

Metabolic profiling of gemcitabine- and paclitaxel-treated immortalized human pancreatic cell lines with K-RASG12D.Semantic proximity Read ↗

Uncoupling the Oncogenic Engine.Semantic proximity Read ↗

Strategies to target energy metabolism in consensus molecular subtype 3 along with Kirsten rat sarcoma viral oncogene homolog mutations for colorectal cancer therapy.Semantic proximity Read ↗

New insights into molecules and pathways of cancer metabolism and therapeutic implicationsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.